- Home
- ANAB vs DJCO Comparison
ANAB vs DJCO Comparison
Compare ANAB & DJCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- DJCO
- Stock Information
- Founded
- ANAB 2005
- DJCO 1987
- Country
- ANAB United States
- DJCO United States
- Employees
- ANAB N/A
- DJCO N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- DJCO Newspapers/Magazines
- Sector
- ANAB Health Care
- DJCO Consumer Discretionary
- Exchange
- ANAB Nasdaq
- DJCO Nasdaq
- Market Cap
- ANAB 621.1M
- DJCO 571.5M
- IPO Year
- ANAB 2017
- DJCO N/A
- Fundamental
- Price
- ANAB $20.14
- DJCO $426.12
- Analyst Decision
- ANAB Buy
- DJCO
- Analyst Count
- ANAB 10
- DJCO 0
- Target Price
- ANAB $48.00
- DJCO N/A
- AVG Volume (30 Days)
- ANAB 500.2K
- DJCO 54.3K
- Earning Date
- ANAB 08-06-2025
- DJCO 08-14-2025
- Dividend Yield
- ANAB N/A
- DJCO N/A
- EPS Growth
- ANAB N/A
- DJCO 115.35
- EPS
- ANAB N/A
- DJCO 70.22
- Revenue
- ANAB $123,164,000.00
- DJCO $79,159,000.00
- Revenue This Year
- ANAB N/A
- DJCO N/A
- Revenue Next Year
- ANAB $24.39
- DJCO N/A
- P/E Ratio
- ANAB N/A
- DJCO $6.12
- Revenue Growth
- ANAB 304.17
- DJCO 10.54
- 52 Week Low
- ANAB $12.21
- DJCO $359.34
- 52 Week High
- ANAB $40.70
- DJCO $602.00
- Technical
- Relative Strength Index (RSI)
- ANAB 31.39
- DJCO 56.20
- Support Level
- ANAB $19.55
- DJCO $408.32
- Resistance Level
- ANAB $22.03
- DJCO $452.53
- Average True Range (ATR)
- ANAB 1.50
- DJCO 14.84
- MACD
- ANAB -0.53
- DJCO 3.44
- Stochastic Oscillator
- ANAB 12.05
- DJCO 61.45
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About DJCO Daily Journal Corp. (S.C.)
Daily Journal Corp publishes newspapers and websites covering California and Arizona and produces several specialized information services. The company operates in two segments: Traditional business and Journal Technologies which includes Journal Technologies, Inc. and Journal Technologies (Canada) Inc. It also serves as a newspaper representative specializing in public notice advertising. The majority of revenue is generated from the Traditional segment.